Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides

Inclusion Criteria: * Patients with mycosis fungoides confirmed by a skin biopsy * Stage I or IIA patients must have been treated previously with prior topical therapies including PUVA, UVB, topical steroids, but not NM within the past 2 years, or topical carmustine (BCNU) * Patients must be otherwise healthy with acceptable organ function. * Prior to initiating study therapy, patients must not have had topical therapy within four weeks * Lab values within normal range * Willing/able to give consent * Must use effective means of contraception if of childbearing potential Exclusion Criteria: * Newly diagnosed mycosis fungoides with no prior therapy * A prior history of treatment with topical NM within the past 2 years or topical carmustine (BCNU) * Use of topical or systemic therapies for MF within four (4) weeks of entry in the study * Patients with a diagnosis of stage IIB-IV MF * Serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent compliance with the requirements of the treatment program * Pregnant or nursing females, or males and females of childbearing potential, not using an effective means of contraception * Patients who have had radiation therapy within one year of study start * Patients who have a history of a higher T score than T2 or a higher N score than N1 * Patients who do not agree to do all labs at one site